← Back to Clinical Trials
Recruiting NCT06840717

NCT06840717 Association Between Genetic Polymorphisms and Type 2 Asthma in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06840717
Status Recruiting
Phase
Sponsor Guangzhou Institute of Respiratory Disease
Condition Asthma in Children
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-01-30
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 14 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-01-30 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.

Eligibility Criteria

Inclusion Criteria: 1. All children with asthma diagnosis accord with the GINA in 2023 edition; 2. Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies; 3. In front of the hospital 2 weeks without antibiotics, systemic hormone medication history; 4. There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc. Exclusion Criteria: 1. Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission; 2. Children with primary immunodeficiency disease; 3. The children and their families failed to cooperate or refused the experimental observation.

Contact & Investigator

Central Contact

Lihong Sun, M.D.

✉ sunlihong9797@126.com

📞 13719240285

Frequently Asked Questions

Who can join the NCT06840717 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 14 Years, studying Asthma in Children. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06840717 currently recruiting?

Yes, NCT06840717 is actively recruiting participants. Contact the research team at sunlihong9797@126.com for enrollment information.

Where is the NCT06840717 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06840717 clinical trial?

NCT06840717 is sponsored by Guangzhou Institute of Respiratory Disease. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology